

ken.sandler@gsa.gov to register to attend the meeting and/or listen in to any or all of these conference calls. To attend the meeting and/or conference calls, submit your full name, organization, email address, and phone number, and which you would like to attend. Requests to attend the June 7, 2017 meeting must be received by 5:00 p.m., EDT, on Friday, May 26, 2017. Requests to listen in to the conference calls must be received by 5:00 p.m., EDT, on Tuesday, April 4, 2017. (GSA will be unable to provide technical assistance to any listener experiencing technical difficulties. Testing access to the Web meeting site in advance of calls is recommended.)

Contact Ken Sandler at ken.sandler@gsa.gov to register to comment during the June 7, 2017 meeting public comment period. Registered speakers/organizations will be allowed a maximum of five minutes each, and will need to provide written copies of their presentations. Requests to comment at the meeting must be received by 5:00 p.m., EDT, on Friday, May 26, 2017. Written comments also may be provided to Mr. Sandler at ken.sandler@gsa.gov by the same deadline.

**Background:** The Administrator of GSA established the Committee on June 20, 2011 (**Federal Register**/Vol. 76, No. 118) pursuant to Section 494 of the Energy Independence and Security Act of 2007 (EISA, 42 U.S.C. 17123). Under this authority, the Committee provides independent policy advice and recommendations to GSA to increase the economic and operational performance of the federal building portfolio and its positive impact on organizational effectiveness, human health and wellbeing.

The Committee has recently proposed two new task groups. The *High Performance Building Adoption task group* will pursue the motion of a committee member to provide recommendations to “accelerate the adoption of high performance [Federal] buildings.” The *Health and Wellness task group* will pursue the motion of a committee member to “develop guidelines to integrate health and wellness features into government facilities programs.”

The conference calls will allow the task groups to coordinate the development of consensus recommendations to the full Committee, which will, in turn, decide whether to proceed with formal advice to GSA based upon these recommendations.

*June 7, 2017 Meeting Agenda:*

- Welcome, Introductions, Updates & Plans for Today
- High Performance Building Adoption: Task Group Report & Discussion

- Working Lunch (with Presentation)
- Health and Wellness: Task Group Report & Discussion
- Topics Proposed by Committee Members
- Public Comment Period
- Closing comments
- Adjourn

Detailed agendas, background information, and updates for the meeting and conference calls will be posted on GSA’s Web site at <http://www.gsa.gov/gbac>.

**Meeting Access:** The Committee will convene its June 7, 2017 meeting at GSA, Room 1153, 1800 F Street NW., Washington DC 20405, and the site is accessible to individuals with disabilities.

Dated: March 13, 2017.

**Kevin Kampschroer,**

*Federal Director, Office of Federal High-Performance Green Buildings, General Services Administration.*

[FR Doc. 2017-05416 Filed 3-17-17; 8:45 am]

**BILLING CODE 6820-14-P**

## OFFICE OF GOVERNMENT ETHICS

### Request for Public Input on the Application of the Criminal Conflict of Interest Prohibition to Certain Beneficial Interests in Discretionary Trusts; Extension of Comment Period

**AGENCY:** Office of Government Ethics (OGE).

**ACTION:** Notice of request for public comments; extension of comment period.

**SUMMARY:** On January 3, 2017, OGE published in the **Federal Register**, 82 FR 122 (Jan. 3, 2017), a request for public input on the application of the criminal conflict of interest prohibition to certain beneficial interests in discretionary trusts. The public comment period closed on March 6, 2017. OGE is extending the comment period to April 20, 2017.

**DATES:** To be assured consideration, comments must be received at the address provided below, by April 20, 2017, though OGE may have some limited ability to review late submissions if workload and other considerations permit.

**ADDRESSES:** You may submit comments, in writing, to OGE regarding this notice and request by any of the following methods:

*Email:* [usoge@oge.gov](mailto:usoge@oge.gov). Include the reference “Request for Input on Discretionary Trusts” in the subject line of the message.

*Fax:* (202) 482-9237.

*Mail/Hand Delivery/Courier:* U.S. Office of Government Ethics, Suite 500, 1201 New York Avenue NW., Washington, DC 20005-3917, Attention: “Request for Input on Discretionary Trusts.”

*Instructions:* All submissions must include OGE’s agency name and the words “Discretionary Trusts.” All comments, including attachments and other supporting materials, will become part of the public record and subject to public disclosure. Comments may be posted on OGE’s Web site, [www.oge.gov](http://www.oge.gov). Sensitive personal information, such as account numbers or Social Security numbers, should not be included. Comments generally will not be edited to remove any identifying or contact information.

**FOR FURTHER INFORMATION CONTACT:**

Jennifer A. Matis, Assistant Counsel, Office of Government Ethics, Suite 500, 1201 New York Avenue NW., Washington, DC 20005-3917; Telephone: 202-482-9300; TTY: 800-877-8339; FAX: 202-482-9237.

**SUPPLEMENTARY INFORMATION:** To be considered, any submission exceeding five (5) pages in length must include a one-page summary of key points and conclusions. Commenters are requested to state briefly the nature of their expertise in trust law. A copy of the original notice of request for public comments, 82 FR 122 (Jan. 3, 2017), is available at: <https://www.gpo.gov/fdsys/pkg/FR-2017-01-03/pdf/2016-31583.pdf>.

Approved: March 14, 2017.

**Walter M. Shaub, Jr.,**

*Director, U.S. Office of Government Ethics.*

[FR Doc. 2017-05454 Filed 3-17-17; 8:45 am]

**BILLING CODE 6345-03-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2016-N-0001]

#### Identification and Characterization of the Infectious Disease Risks of Human Cells, Tissues, and Cellular and Tissue-Based Products; Public Workshop; Correction

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of public workshop; correction.

**SUMMARY:** The Food and Drug Administration (FDA) is correcting a notice that appeared in the **Federal Register** of Thursday, December 29, 2016. The document announced a

public workshop entitled “Identification and Characterization of the Infectious Disease Risks of Human Cells, Tissues, and Cellular and Tissue-based Products.” The document was published with an error in the Web site address to access the transcript of the workshop. This document corrects that error.

**FOR FURTHER INFORMATION CONTACT:**

Monica Kapoor, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 3111C, Silver Spring, MD 20993, [CBERPublicEvents@fda.hhs.gov](mailto:CBERPublicEvents@fda.hhs.gov); or Staci Revette, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 3109B, Silver Spring, MD 20993, [CBERPublicEvents@fda.hhs.gov](mailto:CBERPublicEvents@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** In the **Federal Register** of Thursday, December 29, 2016, in FR Doc. 2016–31628, on page 96008, the following correction is made:

On page 96008, in the second column under the *Transcripts* caption of section III, *Participating in the Public Workshop*, the third sentence in the fourth paragraph is corrected to read, “Please be advised that as soon as a transcript of the public workshop is available, it will be accessible at: <http://www.fda.gov/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/ucm525001.htm>.”

Dated: March 14, 2017.

**Leslie Kux,**

*Associate Commissioner for Policy.*

[FR Doc. 2017–05417 Filed 3–17–17; 8:45 am]

**BILLING CODE 4164–01–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

[Docket No. FDA–2016–N–4620]

**Agency Information Collection Activities; Proposed Collection; Comment Request; Medical Devices; Reports of Corrections and Removals**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal Agencies are

required to publish notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the submission of reports of corrections and removals that are associated with medical and radiation emitting products regulated by FDA’s Center for Devices and Radiological Health.

**DATES:** Submit either electronic or written comments on the collection of information by May 19, 2017.

**ADDRESSES:** You may submit comments as follows:

*Electronic Submissions*

Submit electronic comments in the following way:

- *Federal eRulemaking Portal:* <https://www.regulations.gov/>. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to <https://www.regulations.gov/> will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on <https://www.regulations.gov/>.

- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).

*Written/Paper Submissions*

Submit written/paper submissions as follows:

- *Mail/Hand delivery/Courier (for written/paper submissions):* Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

- For written/paper comments submitted to the Division of Dockets Management, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”

*Instructions:* All submissions received must include the Docket No. FDA–2016–N–4620 for “Agency Information Collection Activities; Proposed Collection; Comment Request; Medical Devices; Reports of Corrections and Removals.” Received comments will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at <https://www.regulations.gov/> or at the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

- **Confidential Submissions—**To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on <https://www.regulations.gov/>. Submit both copies to the Division of Dockets Management. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as “confidential.” Any information marked as “confidential” will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: <https://www.fda.gov/regulatoryinformation/dockets/default.htm>.

*Docket:* For access to the docket to read background documents or the electronic and written/paper comments received, go to <https://www.regulations.gov/> and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Division of Dockets Management, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

**FOR FURTHER INFORMATION CONTACT:** FDA PRA Staff, Office of Operations, Food and Drug Administration, Three White Flint North, 10A63, 11601 Landsdown St., North Bethesda, MD 20852, [PRAStaff@fda.hhs.gov](mailto:PRAStaff@fda.hhs.gov).